Clinuvel Pharmaceuticals Ltd
OTC:CLVLY

Watchlist Manager
Clinuvel Pharmaceuticals Ltd Logo
Clinuvel Pharmaceuticals Ltd
OTC:CLVLY
Watchlist
Price: 8.21 USD -1.2% Market Closed
Market Cap: 423.5m USD

Clinuvel Pharmaceuticals Ltd
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Clinuvel Pharmaceuticals Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Revenue
AU$95m
CAGR 3-Years
13%
CAGR 5-Years
23%
CAGR 10-Years
38%
Opthea Ltd
ASX:OPT
Revenue
$25k
CAGR 3-Years
-35%
CAGR 5-Years
-16%
CAGR 10-Years
-30%
Mesoblast Ltd
ASX:MSB
Revenue
$17.2m
CAGR 3-Years
19%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
CSL Ltd
ASX:CSL
Revenue
$15.6B
CAGR 3-Years
14%
CAGR 5-Years
11%
CAGR 10-Years
11%
Telix Pharmaceuticals Ltd
ASX:TLX
Revenue
AU$507.9m
CAGR 3-Years
306%
CAGR 5-Years
171%
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Revenue
AU$26.2m
CAGR 3-Years
18%
CAGR 5-Years
59%
CAGR 10-Years
41%
No Stocks Found

Clinuvel Pharmaceuticals Ltd
Glance View

Market Cap
411.5m USD
Industry
Biotechnology

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). The company is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.

CLVLY Intrinsic Value
11.64 USD
Undervaluation 29%
Intrinsic Value
Price

See Also

What is Clinuvel Pharmaceuticals Ltd's Revenue?
Revenue
95m AUD

Based on the financial report for Jun 30, 2025, Clinuvel Pharmaceuticals Ltd's Revenue amounts to 95m AUD.

What is Clinuvel Pharmaceuticals Ltd's Revenue growth rate?
Revenue CAGR 10Y
38%

Over the last year, the Revenue growth was -1%. The average annual Revenue growth rates for Clinuvel Pharmaceuticals Ltd have been 13% over the past three years , 23% over the past five years , and 38% over the past ten years .

Back to Top